ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Atherosclerosis"

  • Abstract Number: 3100 • 2016 ACR/ARHP Annual Meeting

    Can Achieving Sustained Minimal Disease Activity (MDA) Prevent Progression of Subclinical Atherosclerosis? a Prospective Cohort Study in Psoriatic Arthritis

    Tsz Ho CHENG1, Qing SHANG2, PW Alex LEE1, Priscilla WONG1, Tracy Y. ZHU3, Chun-Kwok WONG4, JW Jack LEE5, M Mimi CHANG6, Edmund LI1 and Lai-Shan TAM7, 1Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, 3Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong, China, 4Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong, 5Biostatistics Division, School of Public and Primary Care, The Chinese University of Hong Kong, Hong Kong, Hong Kong, 6Department of Medicine & Therapeutics, Prince of Wales Hospital, Hong Kong, Hong Kong, 7Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China

    Background/Purpose: Patients with PsA were reported to have a higher incidence of cardiovascular disease (CVD) and subclinical carotid atherosclerosis due to underlying inflammation. Minimal disease…
  • Abstract Number: 1485 • 2016 ACR/ARHP Annual Meeting

    Generation of New Carotid Plaque Is Determined By the Prexisting Carotid Atherosclerosis and Ongoning Disease Activity of Rheumatoid Arthritis

    Jong Wan Kang1, Eun Song Lee2, Jung Su Eun1, Na Ri Kim1, Ji Hun Kim3, Jin Young Kang4, Eon Jeong Nam1 and Young Mo Kang5, 1Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South Korea, 2Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, The Republic of, 3Division of Rheumatology, Department of Internal Medicine, College of Medicine, Kyungpook National University Hospital, Daegu, South Korea, 4Dept of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, Republic of

    Background/Purpose:   This study shows that carotid plaque at year 5 is predicted by IMT and dyslipidemia at baseline, whereas formation of new plaques after…
  • Abstract Number: 3101 • 2016 ACR/ARHP Annual Meeting

    Lipoprotein Profile and Serum Glycoprotein Acetylation As Markers of Cardiovascular Risk in Systemic Lupus Erythematosus

    Simantini Sakhardande1, Monica Purmalek1, Yenealem Temesgen-Oyelakin2, Maureen Sampson3, Aditya Joshi4, Alice Fike5, Michael Davis6, Taufiq Salahuddin7, Balaji Natarajan7, Joseph Lerman7, Zerai G. Manna8, Amit Dey9, Marcus Chen7, Sarfaraz Hasni8, Nehal N. Mehta7, Alan Remaley7 and Mariana Kaplan10, 1Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases,, National Institutes of Health, Bethesda, MD, 3Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD, 4National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, 5National Institutes of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 6NIH, Bethesda, MD, 7NHLBI, National Institutes of Health, Bethesda, MD, 8National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 9National Institutes of Health, Bethesda, MD, 10NIAMS/NIH, Bethesda, MD

    Background/Purpose:  The risk of atherosclerotic cardiovascular disease (CVD) is significantly increased in systemic SLE compared to age and gender matched controls. The implementation of nuclear…
  • Abstract Number: 1653 • 2016 ACR/ARHP Annual Meeting

    Delineating the Effects of Rheumatoid Arthritis Pharmacotherapies on Vascular Inflammation: Rationale and Design of a Clinical Trial

    Jon T. Giles1, Katherine Liao2, Nina Paynter3, Alyssa Wohlfahrt4, Afshin Zartoshti5, Rachel Broderick6, Daniel H. Solomon7 and Joan Bathon6, 1Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, 2Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, 3Medicine, Harvard University, Boston, MA, 4Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 5Rheumatology, Columbia University, College of Physicians & Surgeons, New York city, NY, 6Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, 7Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose:  Rheumatoid arthritis is associated with an excess cardiovascular disease (CVD) burden. Fewer CVD events associated with specific DMARD therapies have been reported; however, causal…
  • Abstract Number: 3102 • 2016 ACR/ARHP Annual Meeting

    Neutrophil Subsets, Arterial Inflammation, and Vascular Stiffness in Patients with Systemic Lupus Erythematosus

    Monica Purmalek1, Simantini Sakhardande1, Yenealem Temesgen-Oyelakin2, Aditya Joshi3, Joseph Lerman4, Michael Davis3, Alice Fike5, Amit Dey6, Taufiq Salahuddin7, Balaji Natarajan3, Martin P. Playford7, Heather Teague3, Zerai G. Manna5, Marcus Chen3, Sarfaraz Hasni5, Nehal N. Mehta7 and Mariana Kaplan1, 1Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases,, National Institutes of Health, Bethesda, MD, 3NIH, Bethesda, MD, 4Clinical Center, NIH, Bethesda, MD, 5National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 6National Institutes of Health, Bethesda, MD, 7NHLBI, National Institutes of Health, Bethesda, MD

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) show a striking increase in risk of atherosclerotic cardiovascular disease (CVD) not explained by Framingham risk, when compared…
  • Abstract Number: 1663 • 2016 ACR/ARHP Annual Meeting

    Assessment of Serum Calprotectin and Osteoprotegerin Levels in a Cohort of Spanish Patients with Axial Spondyloarthritis

    Fernanda Genre1, Carlos Fernández-Díaz1, Javier Rueda-Gotor1, Raquel López-Mejías1, Sara Remuzgo-Martínez1, Begoña Ubilla1, Veronica Mijares1, Alfonso Corrales1, Virginia Portilla1, Patricia Fuentevilla1, Luis Rodriguez-Rodriguez2, Ricardo Blanco1, José Luis Hernandez3 and Miguel Angel Gonzalez-Gay1,4,5, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, 2Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, 3Bone Metabolism Unit, Department of Internal Medicine, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, RETICEF, Santander, Spain, 4School of Medicine, University of Cantabria, Santander, Spain, 5Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose:  Calprotectin is a protein involved in several cellular processes including immunomodulation1. Elevated levels of this protein have been observed in inflammatory diseases, since it…
  • Abstract Number: 1676 • 2016 ACR/ARHP Annual Meeting

    Methotrexate and Anti-Tumor Necrosis Treatment Improve Endothelial Function in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

    Gia Deyab1, Ingrid Hokstad2, Stefan Agewall3, Torstein Lyberg4, Jon Elling Whist5, Milada Cvancarova Småstuen6, Gunnbjørg Hjeltnes7 and Ivana Hollan8,9,10,11, 1Department of Medical Biochemistry, Innlandet Hospital Trust, Lillehammer, Norway, 2Lillehammer Hospitat for Rheumatic Diseases, Lillehammer, Norway, 3University of Oslo, Oslo, Norway, 4Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, 5Innlandet Hospital Trust, Lillehammer, Norway, 6Institution of health care - Health science PhD program, Oslo and Akershus University College, Oslo, Norway, 7Medicine, Innlandet Hospital Trust, Lillehammer, Norway, 8Harvard Medical School, Boston, MA, 9Department of Medicine, Brigham and Women's Hospital, Boston, MA, 10Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 11Innlandet Hospital Trust, Brumunddal, Norway

    Background/Purpose: Inflammatory rheumatic diseases (IRDs) are associated with accelerated atherosclerosis, which progression is related to inflammation (1). One of the first stages in atherogenesis is…
  • Abstract Number: 1682 • 2016 ACR/ARHP Annual Meeting

    Tnfα Inhibitors Are Associated with Reduced Progression of Carotid Atherosclerotic Plaques By Ultrasound and an Improvement in Aortic Arch Vascular Inflammation By 18-FDG PET/CT in Psoriasis and Psoriatic Arthritis Patients – a Prospective Study from Two Cohorts

    Lihi Eder1, Aditya Joshi2, Vinod Chandran3, Amit Dey4, Richard J. Cook5, Abhishek Chaturvedi6, Dafna D. Gladman7 and Nehal Mehta8, 1Medicine, University of Toronto, Women's College Hospital, Toronto, ON, Canada, 2National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, 3Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4National Institutes of Health, Bethesda, MD, 5Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, 6National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, 7Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 8National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD

    Background/Purpose:  Psoriasis (PSO) and psoriatic arthritis (PsA) are chronic inflammatory diseases which are associated with increased cardiovascular (CV) diseases. Observational studies have found that TNFα…
  • Abstract Number: 1770 • 2016 ACR/ARHP Annual Meeting

    The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the First 10 Years

    Murray Urowitz1, Dafna D Gladman2, Nicole Anderson3, Jiandong Su4 and The Systemic Lupus International Collaborating Clinics (SLICC) Group , 1Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 4Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada

    The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the first 10 years   Background/Purpose: The Medical Outcome Survey Short Form…
  • Abstract Number: 1786 • 2016 ACR/ARHP Annual Meeting

    Long-Term Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus in a Large Case Control Cohort Study

    Konstantinos Tselios1, Dafna D Gladman2, Jiandong Su3, Olga Ace4 and Murray Urowitz5, 1Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose:  Certain traditional and disease-related factors have been identified to accelerate atherosclerosis in systemic lupus erythematosus (SLE). Due to the lack of long-term prospective studies,…
  • Abstract Number: 1790 • 2016 ACR/ARHP Annual Meeting

    Accrual of Disease Comorbidities over 8 Years in a Multicentre Inception SLE Cohort

    Murray Urowitz1, Dafna D Gladman2, Nicole Anderson3, Jiandong Su4 and The Systemic Lupus International Collaborating Clinics (SLICC) Group, 1Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 4Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada

    Background/Purpose: The annual accrual of comorbidities in patients with SLE is not well described.  We report the annual occurrence of these features in an inception…
  • Abstract Number: 738 • 2016 ACR/ARHP Annual Meeting

    Preventive Effect of Combined Treatment with Bisphosphonate and Vitamin D on Atherosclerosis in Patients with Systemic Lupus Erythematosus

    Kazumasa Ohmura, Masaru Kato, Toshiyuki Watanabe, Ryo Hisada, Masatoshi Kanda, Sanae Shimamura, Ikuma Nakagawa, Yuka Shimizu, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

    Background/Purpose: Premature atherosclerosis is one of the major complications of systemic lupus erythematosus (SLE). Preventing atherosclerosis is a key objective while monitoring patients with SLE.…
  • Abstract Number: 2168 • 2016 ACR/ARHP Annual Meeting

    Metabolic Syndrome, All Cause Mortality and Atherosclerotic Cardiovascular Disease in Rheumatic Diseases

    Marco Antivalle1,2, Valentina Varisco2, Alessandra Mutti2, Alberto Batticciotto2, Maria Chiara Ditto2, Fabiola Atzeni3 and Piercarlo Sarzi-Puttini2, 1Rheumatology, Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, 2Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, 3Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy

    Background/Purpose:  all-cause and cardiovascular mortality and cardiovascular morbidity are reportedly increased in rheumatic diseases, both inflammatory and non-inflammatory. Few studies, however have addressed the impact…
  • Abstract Number: 880 • 2016 ACR/ARHP Annual Meeting

    Pilot Study of Microbubble Contrast-Enhanced Vascular Ultrasonography: A Novel Method of Detecting Large Vessel Vasculitis?

    Kimberly P. Liang1, Douglas P. Landsittel2, Bernadette B. Sendon3, Donald M. Jones4, Suresh R. Mulukutla5, Steven E. Reis6, Ali Hakim Shoushtari7 and Larry W. Moreland8, 1Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 2Medicine, University of Pittsburgh, Pittsburgh, PA, 3Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 4Rheumatology & Clinical Immunology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 5Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, 6Division of Cardiology and Department of Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, 7Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, 8Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose:   A key unmet need in the monitoring of disease activity in large vessel vasculitides (LVV), i.e., giant cell arteritis (GCA) and Takayasu arteritis…
  • Abstract Number: 2425 • 2016 ACR/ARHP Annual Meeting

    The Vasculopathy of Juvenile Dermatomyositis (JDM); Evidence of Persistent Endothelial Injury, Hypercoagulability, Subclinical Inflammation and Increased Arterial Stiffness

    Charalampia Papadopoulou1,2, Ying Hong1, Petra Krol1,2, Yiannis Ioannou3, Clarissa Pilkington2,4,5, Hema Chaplin6, Stephanie Simou1, Marietta Charakida7, Lucy R Wedderburn5,8,9, Paul Brogan10 and Despina Eleftheriou1,8,11, 1Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, 2Paediatric Rheumatology, Great Ormond Street Hospital NHS Trust, London, United Kingdom, 3Rayne Institute, Arthritis Research UK Centre for Adolescent Rheumatology, UCL Division of Medicine, London, United Kingdom, 4Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 5Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, 6Centre for Adolescent Rheumatology, Arthritis Research UK, London, United Kingdom, 7Vascular Physiology Unit, Institute of Cardiovascular Science , University College London, London, United Kingdom, 8Paediatric Rheumatology Department, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 9Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, 10Department of Paediatric Rheumatology, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 11Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom

    Background/Purpose:  Vasculopathy is considered central to the pathogenesis of Juvenile Dermatomyositis (JDM). The interplay between persistent JDM-vasculopathy, traditional cardiovascular risk factors, exposure to corticosteroids, and…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 17
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology